Sign up to access historical data
Similar companies
What is Crispr Therapeutics' current ESG score, and what does it signify?
Crispr Therapeutics' ESG score of 43 suggests a need for improvement in its sustainability and ethical practices. It falls below the industry average, indicating potential areas of concern.
Analyzing ESG, how is Crispr Therapeutics performing compared to its industry peers?
Compared to its peers, Crispr Therapeutics ranks in the 52nd percentile when it comes to ESG.
Why is tracking the ESG score important for investors?
ESG scores are crucial for investors as they provide insights into a company's long-term sustainability and ethical practices. High scores can indicate lower risk and a commitment to future-proofing, which is increasingly important to socially conscious investors.
How often does AltIndex update the ESG scores for companies like Crispr Therapeutics?
AltIndex updates the ESG scores for companies, including Crispr Therapeutics, on a monthly basis. This ensures that investors have the latest data to gauge the company's ongoing commitment to environmental, social, and governance standards.
Sign up and get more insights on Crispr Therapeutics.
